Residual CVD Risk Niacin and Simvastatin P. Pauletto Medicina Interna I^, Treviso University of Padova - Italy.

Slides:

Advertisements

Similar presentations

Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia N Engl J Med Mar 11;362(10): Paul W. Ladenson, M.D., Jens D.

Advertisements

Niacin Use in Patients with Low HDL-Cholesterol Receiving Intensive Statin Therapy William E. Boden, MD, FACC, FAHA Jeffrey Probstfield, MD, FACC, FAHA.

Lipoprotein Management. Step 1: Assess clinical CHD risk (Very-High, High, Moderately-High, Moderate, Low Risk) Step 2: Establish goals of therapy appropriate.

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Residual risk: Is LDL target enough?

Secretory Phospholipase A2: A New Risk Factor and Soon a New Target of Therapy Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Division of.

Atorvastatin in Type 2 diabetics on dialysis: 4D Study 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF;

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Lipid Disorders and Management in Diabetes

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The efFects of Pharmacological management of lipids in patients with CKD Andrew Monson FY1 18/9/14.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

Cholesterol and Lipids TIPS Wokefield Park 15/5/2013.

Diagnosis and Treatment of Dyslipidemia  New guidelines are based on the “Adult Treatment Plan III (ATP III)” 2004  Focus = multiple risk factor assessment.

Treatment of Dyslipidemia SDPI CGP Healthy Heart Project March 8, 2006.

TC LDL- C HDL- C Nonfatal MI/CHD death CHD death All- cause mortality *As compared to placebo. † P= CARE: Effect of Lipid Lowering on Lipid Values.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

Dyslipidemia: What Every Resident Should Know

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Is Low HDL-C a Modifiable Risk Factor or Only a Risk Marker for CHD

Christie M. Ballantyne, MD

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Cholesterol Lowering and CV Risk: Meta-analyses

Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.

AIM HIGH Niacin plus Statin to prevent vascular events

First time a CETP inhibitor shows reduction of serious CV events

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

Oxford Niacin Trial.

Raising HDL Cholesterol

FATS- Familial Atherosclerosis Treatment Study

TNT: Baseline and final LDL cholesterol levels

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

An Endocrinology Clinic in Dyslipidemia

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Patient 1: 53-Year-Old Man With CVD Risk Factors

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Lipid Disorders and Management in Diabetes- Part 1

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

TNT Study: Baseline Characteristics of the Patients

62-year-old Man With Unstable Angina

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p < for noninferiority)

LRC-CPPT and MRFIT Content Points:

(p = for noninferiority)

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Potential mechanisms whereby statins may reduce the risk of stroke

Cause of death Treatment-arm events, % (n=45 054)

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry.

Updates on Dyslipidemia

PROSPER: trial design

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

FIELD: Primary outcome

in diabetic patients with mixed dyslipidemia

ATP III Guidelines Drug Therapy FUTURE RESEARCH.

Section 6: Update on lipid treatment guidelines

Presentation transcript:

Residual CVD Risk Niacin and Simvastatin P. Pauletto Medicina Interna I^, Treviso University of Padova - Italy

Time to the first primary clinical end point (death from coronary causes, nonfatal MI, stroke, or revascularization) Brown BG et al. N Engl J Med 2001;345:1583

Stenosis (%) and minimal luminal diameter for nine proximal lesions, for all lesions, and for lesions in various categories of base-line severity, according to treatment group. Brown BG et al. N Engl J Med 2001;345:1583

Dose ranges and efficacy of statins, ezetimibe, and bile acid sequestrants Runhua H et al. Endocrinol Metab Clin N Am 2009;38:79

Residual CVD Risk After Statin Therapy Alagona P. Am J Manag Care 2009;15:s65

Low HDL-C Is Associated With High CVD Risk Even If LDL-C Levels Are Well-Controlled (TNT Study) Alagona P. Am J Manag Care 2009;15:s65

Strategies for Reducing CHD Risk Alagona P. Am J Manag Care 2009;15:s65

Efficacy of niacin ER/simvastatin combination therapy: SEACOAST I Alagona P. Am J Manag Care 2009;15:s65

Efficacy of niacin ER/simvastatin combination therapy: SEACOAST II Alagona P. Am J Manag Care 2009;15:s65

Fenofibric Acid and Rosuvastatin Combination Therapy in Patients With Mixed Dyslipidemia Alagona P. Am J Manag Care 2009;15:s65